Left ventricular (LV) systolic function is a major prognostic determinant in coronary artery disease, and a close relation between LV ejection fraction (LVEF) and mortality has been demonstrated.[@b1; @b2; @b3; @b4] In the clinical setting, echocardiography is a commonly used method for determination of LV function. In addition to evaluation of LVEF, Doppler echocardiography also permits assessment of the degree of mitral regurgitation (MR). Although long recognised as a prognostic factor in heart failure and myocardial infarction (MI),[@b5; @b6; @b7; @b8] limited data are available on the prognostic value of MR in the full spectrum of acute coronary syndromes (ACS).[@b9]

Circulating levels of B-type natriuretic peptide (BNP), a cardiac-derived biomarker, are associated with LV function, and BNP has emerged as an important diagnostic tool in congestive heart failure (CHF). BNP and the N-terminal fragment (NT-proBNP) of its prohormone (proBNP) have also been shown to be independently predictive of mortality in patients with ACS,[@b3] [@b4] as well as in patients with stable coronary disease.[@b2] [@b10] Notably, in patients with asymptomatic or symptomatic MR and decreased LVEF, BNP has been shown to increase in proportion to the severity of MR.[@b11] Moreover, in a study of consecutive patients with CHF, a significant association between higher levels of BNP and moderate to severe MR was observed,[@b12] suggesting that some of the prognostic merit of BNP may be ascribed to its reflection of the magnitude of MR. It is unknown, however, whether indices of LV systolic function, MR severity and BNP levels provide independent and incremental prognostic information to each other. Thus, in the present study we first sought to evaluate whether MR adds prognostic information above that obtained from BNP and LVEF in ACS. Second, we assessed whether the presence of significant MR, increased BNP levels and decreased LVEF, alone or in combination, provided prognostic information above and beyond conventional clinical risk factors for the long-term outcome in ACS.

Methods
=======

Patient population
------------------

Consecutive patients admitted to the coronary care unit of the Sahlgrenska University Hospital, Gothenburg, Sweden with suspected ACS and evaluated for participation in a study of prognosis and its prediction in ACS,[@b13] were included between December 1996 and March 2001. To enable long-term follow-up, only patients aged \<80 years and living within the catchment area of the hospital were eligible. Patients transferred from other hospitals for tertiary care were not included. The main exclusion criteria were severe non-coronary artery disease associated with a life expectancy of \<1 year or unwillingness to participate. A patient could only be included once.

The suspicion of ACS had to be supported by ECG changes on admission, biochemical markers above the upper reference level or previously recognised coronary artery disease.[@b13]

Based on ECG and biochemical markers of myocardial ischaemia and necrosis, the patients were diagnosed as ST-segment elevation MI (STEMI), non-STEMI or unstable angina pectoris (UAP). STEMI was further subdivided according to anterior (including lateral), inferior (including posterior) and unspecified locations.

Information on earlier hospital admissions, risk factors and medication was obtained from hospital medical records and personal interviews. Date of death and survival confirmation at 1 January 2008 was obtained from the Swedish National Population Registry, and information on rehospitalisation for CHF (International Statistical Classification of Disease, Ninth Revision (ICD-9) code 428 or Tenth Revision (ICD-10) code 150) up to January 2008 from the Swedish Hospital Discharge Register.

Blood samples
-------------

Peripheral blood samples for plasma BNP determination were obtained in the acute phase within 24 h of hospital admission by direct venipuncture of an antecubital vein after the patient had been in the supine position for \>30 min. The samples were drawn into prechilled ethylenediamine tetraacetic acid (EDTA) tubes, immediately placed on ice and centrifuged at 3000 rpm within 1 h. EDTA plasma samples were aspirated and stored at −80°C until analysis (median (25th, 75th percentiles) 58 (46, 81) months). BNP levels in plasma were measured by a fluorescence immunoassay from Biosite Diagnostics (San Diego, California, USA). Interassay and intra-assay coefficients of variation for the BNP measurements were 9--12% in the low, medium and high ranges. There was a weak inverse relation between BNP levels and days of storage (r=−0.076, p=0.042). Glomerular filtration rate was estimated by the Cockroft and Gault formula. Renal dysfunction was defined as calculated creatinine clearance \<60 ml/min.

Echocardiography
----------------

Echocardiographic investigations including continuous wave Doppler recordings were performed by an experienced operator within 5 days after hospital admissions. Biplane LVEF was calculated by the disc summation method and tracings were checked in motion mode for accuracy, as described previously.[@b3] [@b14] LVEF \<0.40 was regarded as reduced systolic LV function.[@b15]

The grade of MR was determined from colour and continuous wave Doppler recordings based on the regurgitation flow intensity and classified into five grades.[@b16] Grade 0 denoted no regurgitation or regurgitation limited to a small part of early systole; grade 1 indicated mild regurgitation weakly visible during the whole of systole; grade 2 was moderate regurgitation clearly visible throughout systole; grade 3 was defined by large regurgitation intensely visible during the whole of systole; and grade 4 signified severe regurgitation as found, for example, in chordal rupture with a large intensity and altered shape of the spectral Doppler profile (sharp and often a visible V wave effect rather than a rounded profile). In grades 3--4 the regurgitation usually reached the roof of the left atrium and, particularly in grade 4, swirled around. In grade 3--4 there was also usually a volume load on the left ventricle and reversed systolic pulmonary venous flow.

Statistical analyses
--------------------

Categorical variables are reported as percentages and continuous variables as medians. We used dichotomised BNP (\>75th percentile), LVEF (\<0.40) and MR (grade \>1) for the analyses. A score defined as the number of these three factors present was also calculated and analysed.

The association between dichotomised BNP, LVEF and MR and baseline demographic characteristics and clinical risk factors was assessed by the Fisher exact test for proportions and the Mann--Whitney U test for continuous/ordered variables.

The Kaplan--Meier method was used for estimation of cumulative mortality curves. In the figures these are only shown for the first 10 years, although the complete follow-up information until 1 January 2008 was used to calculate HRs and p values. Univariate mortality comparisons were performed using the log rank test, and multivariate mortality analyses as well as HR calculations (with corresponding 95% CIs) were performed using the Cox proportional hazards model. In the multivariable analyses we adjusted for potential confounders deemed to be clinically relevant (age, gender, smoking, diabetes, hypertension, hypercholesterolaemia, prior MI, prior angina, prior CHF, prior percutaneous coronary intervention/coronary artery bypass grafting, estimated creatinine clearance and diagnosis). All p values are two-tailed and considered significant if \<0.05.

Results
=======

The study population comprised 725 patients (515 men and 210 women) of mean±SD age 65±10 years with STEMI (n=343), non-STEMI (n=256) or UAP (n=126). BNP measurements were performed in the acute phase and an echocardiographic examination with estimation of LVEF and the degree of MR was carried out within 5 days of admission. Among all the patients the MR grade was inversely related to LVEF (r=−0.32, p\<0.0001) and directly related to BNP (r=0.41, p\<0.0001).

Ninety patients (12%) had an MR grade \>1, 110 patients (15%) had an LVEF \<0.40 and 180 patients (25%) had BNP levels above the 75th percentile (373 pg/ml). The characteristics of all the patients are shown in [table 1](#tbl1){ref-type="table"} with patients divided into the following subgroups: with or without significant MR, with or without depressed LV function and with BNP above or below the 75th percentile. Patients in the groups with significant MR, low LVEF and high BNP were older and more often had a history of MI and CHF. Hypertension and previous angina were more common in the groups with MR grade \>1 and higher BNP, while there was no difference between the LVEF subgroups. The proportion of women was higher among patients with high BNP and tended to be high in patients with MR. Previous revascularisation and diabetes were more common in patients with MR than in those without. There were no differences in index diagnosis between the MR groups or between the LVEF groups, but non-STEMI was more common in patients with high BNP levels than in those with lower levels, while the opposite was true for UAP. In the subgroups of STEMI, anterior location was associated with lower LVEF (p\<0.0001) and a higher BNP level (p=0.001) but lower MR grade (p=0.027) than inferior location. As shown in [table 1](#tbl1){ref-type="table"}, in patients with larger MR the proportion of anterior MI was lower and the proportion of inferior MI tended to be higher than in those with minor MR. On the other hand, with LVEF \<0.40 anterior MI was more prevalent and inferior MI was less prevalent than with LVEF ≥0.40.

###### 

Baseline characteristics of patients above or below the respective cut-off levels for MR grade, LVEF and plasma BNP

  ------------------------------------------------------------------------------------------------------------------------------------------------------
                              All patients\   MR \>1/≤1\   p Value    LVEF \<0.40/≥0.40 (n=110/615)   p Value    BNP \>373/≤373 (n=180/545)   p Value
                              (n=725)         (n=90/635)                                                                                      
  --------------------------- --------------- ------------ ---------- ------------------------------- ---------- ---------------------------- ----------
  Mean age (years)            65              70/64        \<0.0001   70/64                           \<0.0001   70/63                        \<0.0001

  Female (%)                  29              39/28        0.05       24/30                           0.17       37/27                        0.01

  History (%)                                                                                                                                 

   MI                         20              36/18        0.0002     36/17                           \<0.0001   29/17                        0.001

   Angina pectoris            40              59/38        0.0002     43/40                           0.60       47/38                        0.04

   CHF                        8               27/5         \<0.0001   22/5                            \<0.0001   17/5                         \<0.0001

   PCI/CABG                   12              21/11        0.02       16/12                           0.21       15/12                        0.24

  Risk factors (%)                                                                                                                            

   Current smoker             34              27/35        0.18       38/33                           0.32       30/35                        0.27

   Diabetes mellitus          18              26/17        0.04       18/18                           0.89       21/17                        0.26

   Hypertension               40              51/39        0.03       42/40                           0.75       51/37                        0.0008

   Hypercholesterolaemia      28              31/28        0.53       32/27                           0.36       24/29                        0.22

   GFR \<60 ml/min            38              62/35        \<0.0001   53/36                           0.001      59/31                        \<0.0001

  Diagnosis (%)                                                                                                                               

   STEMI                      47              43/48        0.43       49/47                           0.76       46/48                        0.73

    Anterior                  48              26/50        0.004      74/43                           \<0.0001   57/45                        0.06

    Inferior                  50              64/49        0.09       19/56                           \<0.0001   39/54                        0.02

    Unspecified               2               10/\<1       0.004      7/1                             0.01       5/1                          0.06

   Non-STEMI                  35              43/34        0.10       39/35                           0.39       46/32                        0.0006

   Unstable angina pectoris   17              13/18        0.37       12/18                           0.10       8/21                         \<0.0001

  10-year mortality (%)       36.3            70.2/31.5    \<0.0001   67.5/30.7                       \<0.0001   56.3/29.4                    \<0.0001
  ------------------------------------------------------------------------------------------------------------------------------------------------------

BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CHF, congestive heart failure; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation, PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.

Two hundred and thirty-five patients (32.4%) died during a median (25th and 75th percentiles) follow-up time of 98 (75, 117) months. MR, reduced LVEF and high BNP levels were all significantly associated with long-term mortality, as shown in [figure 1](#fig1){ref-type="fig"} and [table 2](#tbl2){ref-type="table"}.

![Kaplan--Meier curves showing the cumulative incidence of death in relation to (A) mitral regurgitation (MR) grade \>1 or ≤1; (B) left ventricular ejection fraction (LVEF) \<0.40 or ≥0.40; and (C) B-type natriuretic peptide (BNP) \>373 pmol/l (75th percentile) or ≤373 pmol/l in patients with acute coronary syndromes.](heartjnl203059fig1){#fig1}

###### 

HRs (95% CIs) for the association of long-term mortality to baseline MR, LVEF and BNP

                                                        Univariate            p Value    Multivariate model 1 including MR, LVEF and BNP (or MR/LVEF[\*](#table-fn1){ref-type="table-fn"} and BNP)   p Value    Multivariate model 2 including MR or LVEF or BNP or MR/LVEF[\*](#table-fn1){ref-type="table-fn"} + confounders[†](#table-fn2){ref-type="table-fn"}   p Value    Multivariate model 3 including MR, LVEF and BNP (or MR/LVEF[\*](#table-fn1){ref-type="table-fn"} and BNP) + confounders[†](#table-fn2){ref-type="table-fn"}   p Value
  ----------------------------------------------------- --------------------- ---------- ----------------------------------------------------------------------------------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  All-cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   MR \>1.0                                             3.25 (2.41 to 4.37)   \<0.0001   2.28 (1.67 to 3.12)                                                                                         \<0.0001   1.82 (1.29 to 2.59)                                                                                                                                  0.0007     1.53 (1.06 to 2.19)                                                                                                                                           0.02
   LVEF \<0.40                                          3.48 (2.63 to 4.61)   \<0.0001   2.38 (1.76 to 3.23)                                                                                         \<0.0001   2.34 (1.70 to 3.22)                                                                                                                                  \<0.0001   1.94 (1.38 to 2.73)                                                                                                                                           0.0001
   BNP \>373 pmol/l                                     2.86 (2.20 to 3.72)   \<0.0001   1.96 (1.47 to 2.61)                                                                                         \<0.0001   1.79 (1.33 to 2.40)                                                                                                                                  0.0001     1.45 (1.06 to 1.99)                                                                                                                                           0.02
   MR/LVEF score[\*](#table-fn1){ref-type="table-fn"}   2.81 (2.33 to 3.38)   \<0.0001   2.33 (1.90 to 2.85)                                                                                         \<0.0001   1.88 (1.51 to 2.34)                                                                                                                                  \<0.0001   1.73 (1.38 to 2.17)                                                                                                                                           \<0.0001
  Readmission to hospital for CHF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   MR \>1.0                                             3.84 (2.52 to 5.86)   \<0.0001   2.58 (1.66 to 4.01)                                                                                         \<0.0001   2.49 (1.56 to 3.96)                                                                                                                                  0.0001     2.08 (1.29 to 3.35)                                                                                                                                           0.003
   LVEF \<0.40                                          5.14 (3.49 to 7.57)   \<0.0001   3.54 (2.33 to 5.38)                                                                                         \<0.0001   4.14 (2.65 to 6.47)                                                                                                                                  \<0.0001   3.41 (2.14 to 5.42)                                                                                                                                           \<0.0001
   BNP \>373 pmol/l                                     3.30 (2.27 to 4.80)   \<0.0001   2.01 (1.34 to 3.03)                                                                                         0.0008     2.12 (1.38 to 3.24)                                                                                                                                  0.0005     1.51 (0.96 to 2.38)                                                                                                                                           0.07
   MR/LVEF score[\*](#table-fn1){ref-type="table-fn"}   3.66 (2.82 to 4.74)   \<0.0001   3.03 (2.29 to 4.02)                                                                                         \<0.0001   2.91 (2.15 to 3.94)                                                                                                                                  \<0.0001   2.66 (1.94 to 3.65)                                                                                                                                           \<0.0001

Per step in 0--1--2 score, where MR grade \>1 and LVEF \<0.40 were assigned one score point each.

Adjusted for age, gender, smoking, diabetes, hypertension, hypercholesterolaemia and history of diabetes, MI, angina, CHF, PCI/CABG, GFR \<60 ml/min and current diagnosis of ACS type.

ACS, acute coronary syndromes; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CHF, congestive heart failure; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation, PCI, percutaneous coronary intervention.

In a model that included MR, LVEF and BNP, all three variables remained significant predictors of mortality ([table 2](#tbl2){ref-type="table"}, multivariate model 1). After adjustment for clinical confounders, each variable also independently predicted death (multivariate model 2). Furthermore, when MR, LVEF and BNP were forced into the same model together with clinical variables (multivariate model 3), all three factors remained significantly associated with long-term mortality (HR for MR 1.53 (95% CI 1.06 to 2.19), p=0.02; HR for LVEF 1.94 (95% CI 1.38 to 2.73), p=0.0001; and HR for BNP 1.45 (95% CI 1.06 to 1.99), p=0.02, [table 2](#tbl2){ref-type="table"}). The C-statistic (81 months of follow-up) for MR alone was 0.594 compared with 0.669 for MR+LVEF and 0.711 for MR+LVEF+BNP.

[Figure 2](#fig2){ref-type="fig"} shows the mortality curves for patients having none, one or 2--3 of significant MR, low LVEF and high BNP, and illustrates how the mortality increases with a higher score ([figure 2A](#fig2){ref-type="fig"}). The combination of the non-invasive variables without BNP is also shown ([figure 2B](#fig2){ref-type="fig"}).

![Cumulative incidence of death in relation to (A) risk score 0, 1 and 2--3 where mitral regurgitation (MR) grade \>1, left ventricular ejection fraction (LVEF) \<0.40 and BNP \>373 pmol/l (75th percentile) yielded one score point each; and (B) risk score 0, 1 and 2 where MR grade \>1 and LVEF \<0.40 contributed one score point each.](heartjnl203059fig2){#fig2}

MR, LVEF and BNP all showed a significant univariate association with readmission to hospital for CHF ([table 2](#tbl2){ref-type="table"}). After adjustment for potential confounders and taken into the same model, MR (HR 2.08, 95% CI 1.29 to 3.35, p=0.003) and LVEF (HR 3.41, 95% CI 2.14 to 5.42, p\<0.0001) still remained significant predictors of readmission to hospital for CHF, while a trend in the same direction was seen for BNP (HR 1.51, 95% CI 0.96 to 2.33, p=0.07).

Discussion
==========

In this prospective outcome study of patients with ACS, the presence of a significant MR had prognostic implications and provided independent information over that obtained from the combination of reduced LVEF, high BNP and clinical risk factors. Thus, MR grade \>1 independently predicted long-term mortality as well as readmission to hospital for CHF.

Prognostic value of mitral regurgitation
----------------------------------------

ACS may result in varying degrees of ischaemic injury and subsequent LV dysfunction. Numerous studies have shown that the degree of LV systolic dysfunction is a major---if not the most important---determinant of long-term outcome in ACS.[@b17] Development of MR during ACS may be due to ischaemic injury of the papillary muscle apparatus and/or dilation of the left ventricle and has been linked to death and development of heart failure in patients with acute MI independently of LVEF and clinical confounders.[@b15] [@b18] [@b19] In addition, MR has been linked with adverse outcome in patients with STEMI undergoing a percutaneous coronary intervention.[@b20] Our results confirm and extend the findings of these previous studies[@b9] [@b15] [@b19] [@b21] [@b22] by showing that MR adds prognostic information to that of LVEF and BNP across the spectrum of ACS.

BNP and mitral regurgitation
----------------------------

The B-type natriuretic peptides BNP and NT-proBNP are associated with the degree of LV dysfunction following ACS, but still provide prognostic information independently of LVEF[@b3] [@b4] [@b23] and the Thrombolysis In MI (TIMI) risk score.[@b24] In the present study we used BNP, which has been found to be as accurate as NT-proBNP for identifying CHF.[@b25] The volume overload and stretch of the atrial and ventricular myocardium associated with MR are potent stimuli for natriuretic peptide release, suggesting that in some patients the prognostic information obtained from BNP is partly derived from its reflection of MR grade. However, although MR is more common in patients with LV dysfunction, the association between MR grade and LVEF is not linear as unloading of the ventricle tends to increase LVEF.[@b26] As confirmed in our patients, despite less LV dysfunction, inferior MI has been found to be associated with a higher incidence of MR than anterior MI, possibly due to more severe geometric changes in the mitral apparatus.[@b27] Accordingly, the interrelationship between reduced LV function, MR grade and circulating BNP levels is a complex one. Indeed, in the current study we show for the first time that the prognostic information obtained from MR grade and BNP in ACS is complementary and significant when LVEF is also considered. In the full multivariable model which included conventional clinical risk factors, MR grade was still providing prognostic information beyond that obtained from BNP and LVEF.

Prognostic value of the score system
------------------------------------

Despite a number of studies on the prognostic value of MR as well as natriuretic peptides after an MI, we found no information on the long-term prognostic value of the combined information from MR, LVEF and BNP in ACS or MI. To determine whether a combination of the three study variables (MR, LVEF and BNP) provided superior prognostic information to that obtained from entering individual variables, we generated a simple score system. Interestingly, a full score in the two-factor model was associated with higher risk than a score of 2--3 points in the three-factor model, suggesting that, even if inclusion of BNP in the model may be helpful for identifying low-risk patients, it seems less important for identifying high-risk patients when LVEF and MR grade are available. Our two-factor score system of MR and LVEF showed a significant association with readmission to hospital for CHF in a multivariate model including both MR/LVEF and BNP. Echocardiography allows determination of several prognostic indicators after acute MI.[@b28] The combined information of MR and LVEF seems to contain strong supplementary prognostic information. An important advantage is that they are easily obtained in the same echocardiographic investigation, which is now often routinely performed in patients with ACS.[@b17]

Strengths and limitations
-------------------------

Strengths of the current study include a large contemporary patient sample and long duration of follow-up. However, there are also potential important limitations.

We stored plasma at −80°C to allow uniform BNP measurements on one occasion with minimal methodological variation. Although we cannot exclude some degradation of BNP over time, only a very weak relation to days of storage was noted.

The study design used does not permit distinction between pre-existing MR and MR developed following the ischaemic event. Clearly, MR existing before the ACS event might also have affected subsequent prognosis. As this hospital admission was the first contact with emergency care for most patients, information on pre-existing MR grade was not generally available in our study cohort. The same limitation has been discussed by Bursi *et al*[@b18] in a cohort study with acute MI, and is a limitation common to this and all similar studies.

Other limitations include the potential effect of a change in the acute treatment strategy of ACS during the study period---that is, a higher proportion of patients underwent early percutaneous coronary intervention in the late part of the recruitment period than in the early part. These treatment changes may have affected the incidence of MR and the predictive values of the study variables to some extent. However, acute reperfusion in patients with MR in relation to MI does not seem to reduce the mortality rate to the level noted with less MR.[@b8] Furthermore, there is no real consensus on how to grade the magnitude of MR. The assessment of MR in our study was based on a semiquantitative grading of continuous and colour Doppler images by an experienced operator, but other methods have also been described.[@b6] [@b18]

Conclusion
==========

In summary, information concerning MR grade provides important prognostic information across the spectrum of ACS. Evaluation of LV function, MR grade and BNP levels each provide complementary prognostic information to conventional clinical risk factors. A scoring system based on these three variables or MR and LVEF alone represents a risk-stratifying instrument of potential clinical utility. However, its validation in a new study cohort is required before it can be generally recommended.
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